US 11,995,557 B2
Tensor network machine learning system
Vid Stojevic, London (GB); Noor Shaker, London (GB); and Matthias Bal, London (GB)
Assigned to KUANO LTD., London (GB)
Appl. No. 16/618,782
Filed by Kuano Ltd., London (GB)
PCT Filed May 30, 2018, PCT No. PCT/GB2018/051471
§ 371(c)(1), (2) Date Dec. 2, 2019,
PCT Pub. No. WO2018/220368, PCT Pub. Date Dec. 6, 2018.
Claims priority of application No. 1708609 (GB), filed on May 30, 2017; and application No. 1714861 (GB), filed on Sep. 15, 2017.
Prior Publication US 2021/0081804 A1, Mar. 18, 2021
Int. Cl. G06N 3/08 (2023.01); G06N 3/045 (2023.01); G06N 3/088 (2023.01); G06N 10/00 (2022.01); G16B 5/20 (2019.01); G16B 15/30 (2019.01); G16B 40/30 (2019.01)
CPC G06N 3/088 (2013.01) [G06N 3/045 (2023.01); G06N 10/00 (2019.01); G16B 5/20 (2019.02); G16B 15/30 (2019.02); G16B 40/30 (2019.02)] 11 Claims
OG exemplary drawing
 
1. A machine learning based method of identifying candidate, small, drug-like molecules, comprising the step of providing molecular orbital representations of drug-like molecules and/or parts of proteins relevant to an interaction with the molecules, as an input to a machine learning system, to predict molecular properties and identify candidate drug-like molecules, in which molecular orbital representations of drug-like molecules and/or parts of proteins relevant to an interaction with the molecules are represented as tensor networks in which the tensor network representations include networks describing states with volume law entanglement that allow for tensor networks describing density matrices, including both those that obey the area law, and those that do not, and arbitrary superpositions of tensor networks, containing elements in general from distinct types of architectures.